Compare WYETH LTD with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs ALEMBIC PHARMA - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD ALEMBIC PHARMA WYETH LTD/
ALEMBIC PHARMA
 
P/E (TTM) x 27.7 15.6 177.7% View Chart
P/BV x 5.3 3.6 149.0% View Chart
Dividend Yield % 1.3 1.1 119.9%  

Financials

 WYETH LTD   ALEMBIC PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
ALEMBIC PHARMA
Mar-19
WYETH LTD/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044664 157.3%   
Low Rs818412 198.4%   
Sales per share (Unadj.) Rs298.6208.7 143.0%  
Earnings per share (Unadj.) Rs57.231.0 184.7%  
Cash flow per share (Unadj.) Rs58.437.1 157.4%  
Dividends per share (Unadj.) Rs17.005.50 309.1%  
Dividend yield (eoy) %1.81.0 178.6%  
Book value per share (Unadj.) Rs249.5144.2 173.0%  
Shares outstanding (eoy) m22.72188.52 12.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.12.6 121.0%   
Avg P/E ratio x16.317.4 93.7%  
P/CF ratio (eoy) x15.914.5 109.9%  
Price / Book Value ratio x3.73.7 100.0%  
Dividend payout %29.717.7 167.4%   
Avg Mkt Cap Rs m21,157101,461 20.9%   
No. of employees `0000.5NA-   
Total wages/salary Rs m4007,467 5.4%   
Avg. sales/employee Rs Th13,787.4NM-  
Avg. wages/employee Rs Th813.0NM-  
Avg. net profit/employee Rs Th2,643.3NM-  
INCOME DATA
Net Sales Rs m6,78339,347 17.2%  
Other income Rs m35394 375.9%   
Total revenues Rs m7,13639,441 18.1%   
Gross profit Rs m1,6178,736 18.5%  
Depreciation Rs m271,152 2.3%   
Interest Rs m6184 3.0%   
Profit before tax Rs m1,9387,493 25.9%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6321,568 40.3%   
Profit after tax Rs m1,3015,844 22.3%  
Gross profit margin %23.822.2 107.4%  
Effective tax rate %32.620.9 156.0%   
Net profit margin %19.214.9 129.1%  
BALANCE SHEET DATA
Current assets Rs m6,98419,577 35.7%   
Current liabilities Rs m2,05614,896 13.8%   
Net working cap to sales %72.611.9 610.6%  
Current ratio x3.41.3 258.5%  
Inventory Days Days9990 110.6%  
Debtors Days Days2445 52.8%  
Net fixed assets Rs m24427,097 0.9%   
Share capital Rs m227377 60.3%   
"Free" reserves Rs m5,44126,811 20.3%   
Net worth Rs m5,66827,188 20.8%   
Long term debt Rs m254,993 0.5%   
Total assets Rs m7,90147,778 16.5%  
Interest coverage x353.341.7 847.3%   
Debt to equity ratio x00.2 2.4%  
Sales to assets ratio x0.90.8 104.3%   
Return on assets %16.512.6 131.0%  
Return on equity %22.921.5 106.8%  
Return on capital %34.023.6 144.2%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1519,453 0.1%   
Fx outflow Rs m2,6776,065 44.1%   
Net fx Rs m-2,66213,388 -19.9%   
CASH FLOW
From Operations Rs m9238,120 11.4%  
From Investments Rs m317-7,556 -4.2%  
From Financial Activity Rs m-481590 -81.5%  
Net Cashflow Rs m7591,153 65.8%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 2.9 389.7%  
FIIs % 7.2 9.1 79.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 13.9 218.7%  
Shareholders   21,978 49,328 44.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   SUVEN LIFESCIENCES  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  SUN PHARMA  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS